The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a combination of avelumab and axitinib was associated with improved progression-free survival (median 13.8 vs 8.4 months) and objective response (51% vs 26%) compared with sunitinib monotherapy in patients with previously untreated advanced renal cell carcinoma (RCC).
Dr Choueiri presented updated findings according to risk factor (favourable, intermediate and poor) and presence/absence of PD-L1 receptors on the tumours of patients with previously untreated advanced RCC in the ongoing JAVELIN Renal 101 trial. In all subgroups, the combination improved progression-free survival and objective response rate compared to sunitinib alone.